HRP20020429B8 - Polimorfni oblik atorvastatin kalcija - Google Patents

Polimorfni oblik atorvastatin kalcija

Info

Publication number
HRP20020429B8
HRP20020429B8 HR20020429A HRP20020429A HRP20020429B8 HR P20020429 B8 HRP20020429 B8 HR P20020429B8 HR 20020429 A HR20020429 A HR 20020429A HR P20020429 A HRP20020429 A HR P20020429A HR P20020429 B8 HRP20020429 B8 HR P20020429B8
Authority
HR
Croatia
Prior art keywords
atorvastatin calcium
polymorph form
form atorvastatin
theta
peak
Prior art date
Application number
HR20020429A
Other languages
English (en)
Croatian (hr)
Inventor
Ayalon Ari
Levinger Michal
Roytblat Sofia
Lifshitz Revital
Niddam Valerie
Aronhime Judith
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HRP20020429A2 publication Critical patent/HRP20020429A2/xx
Publication of HRP20020429B1 publication Critical patent/HRP20020429B1/xx
Publication of HRP20020429B8 publication Critical patent/HRP20020429B8/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
HR20020429A 1999-11-17 2000-11-16 Polimorfni oblik atorvastatin kalcija HRP20020429B8 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16615399P 1999-11-17 1999-11-17
PCT/US2000/031555 WO2001036384A1 (en) 1999-11-17 2000-11-16 Polymorphic form of atorvastatin calcium

Publications (3)

Publication Number Publication Date
HRP20020429A2 HRP20020429A2 (en) 2004-04-30
HRP20020429B1 HRP20020429B1 (en) 2006-05-31
HRP20020429B8 true HRP20020429B8 (hr) 2007-03-31

Family

ID=22602039

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020429A HRP20020429B8 (hr) 1999-11-17 2000-11-16 Polimorfni oblik atorvastatin kalcija

Country Status (20)

Country Link
EP (3) EP1235799B1 (https=)
JP (2) JP2003514798A (https=)
KR (1) KR20020063190A (https=)
CN (1) CN1423634A (https=)
AT (2) ATE478665T1 (https=)
AU (1) AU783002B2 (https=)
CA (1) CA2392096C (https=)
CZ (1) CZ20021642A3 (https=)
DE (2) DE60044884D1 (https=)
ES (2) ES2234699T3 (https=)
HR (1) HRP20020429B8 (https=)
HU (1) HUP0203257A3 (https=)
IL (2) IL149681A0 (https=)
PL (1) PL355805A1 (https=)
PT (2) PT1535613E (https=)
SI (2) SI1235799T1 (https=)
SK (1) SK286789B6 (https=)
WO (1) WO2001036384A1 (https=)
YU (1) YU35802A (https=)
ZA (1) ZA200203755B (https=)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
KR100704213B1 (ko) * 2000-11-03 2007-04-10 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미-칼슘 ｖｉｉ형
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622477A1 (en) 2000-12-27 2002-07-04 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
BR0210666A (pt) * 2001-06-29 2004-10-05 Warner Lambert Co Formas cristalinas do sal de cálcio do ácido [r-(r*,r*)]-2-(4-fluorofenil)-beta, delta-dihidróxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)c arbonil]-1h-pirrol-1-heptanóico (2:1) (atorvastatina)
US7074818B2 (en) 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
AU2002255479B2 (en) 2001-07-30 2008-09-11 Dr. Reddy's Laboratories Ltd. Crystalline forms VI and VII of atorvastatin clacium
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CA2475864A1 (en) * 2002-02-15 2003-08-28 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
HRP20040767A2 (en) 2002-02-19 2004-12-31 Teva Pharma Desolvating solvates of atorvastatin hemi-calcium
ATE409476T1 (de) * 2002-06-13 2008-10-15 Novartis Pharma Gmbh Calciumsalze von statinen aus indol
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
WO2004050618A2 (en) * 2002-11-28 2004-06-17 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
CA2465693A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
CA2649054A1 (en) 2004-05-05 2005-11-10 Pfizer Products Inc. Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
JP2008506764A (ja) 2004-07-20 2008-03-06 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態
WO2006037125A1 (en) 2004-09-28 2006-04-06 Teva Pharmaceutical Industries Ltd. Process for preparing forms of atorvastatin calcium substantially free of impurities
CN101039906A (zh) 2004-10-18 2007-09-19 特瓦制药工业有限公司 通过将盐溶解于有机溶剂并除去该溶剂来制备无定形阿托伐他汀半钙的方法，所述有机溶剂为醇和酮和 /或酯的混合物
WO2006046109A1 (en) 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
WO2006054308A2 (en) 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
CA2499047A1 (en) 2005-03-01 2006-09-01 Apotex Pharmachem Inc. Process for producing atorvastatin hemicalcium
AU2006281229A1 (en) 2005-08-15 2007-02-22 Arrow International Limited Crystalline and amorphous sodium atorvastatin
EP1924555B1 (en) * 2005-08-15 2014-10-08 Arrow International Limited Process for the preparation of crystalline sodium atorvastatin
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
EP1808162A1 (en) 2005-11-21 2007-07-18 Teva Pharmaceutical Industries Ltd. Atorvastatin pharmaceutical formulation
EP1923057A1 (en) 2005-11-21 2008-05-21 Teva Pharmaceutical Industries Ltd Atorvastatin pharmaceutical formulation
ATE466840T1 (de) 2005-11-21 2010-05-15 Warner Lambert Co Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium
US8080672B2 (en) 2005-12-13 2011-12-20 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
AU2007219107B2 (en) * 2006-02-22 2012-12-06 Mylan Laboratories Ltd. New crystalline form of Atorvastatin hemi-calcium
JP2010520273A (ja) * 2007-03-02 2010-06-10 ドン・ア・ファーム・カンパニー・リミテッド ピロリルヘプタン酸誘導体の新規な結晶形態
US8664390B2 (en) 2007-06-29 2014-03-04 Generics (Uk) Limited Process for the introduction of hydroxyethoxy side chain in bosentan
WO2009007856A2 (en) * 2007-07-11 2009-01-15 Actavis Group Ptc Ehf Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
NZ585438A (en) 2007-10-24 2012-09-28 Generics Uk Ltd Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide
CA2712860C (en) 2008-02-08 2014-11-18 Abhay Gaitonde Process for preparing bosentan
CA2741928A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
EP2373609B1 (en) * 2008-12-19 2013-10-16 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2327682A1 (en) * 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN102249978A (zh) * 2011-06-09 2011-11-23 浙江金立源药业有限公司 阿托伐他汀钙的ky晶型及制备方法
CN103483238B (zh) * 2013-08-20 2014-12-31 蚌埠丰原医药科技发展有限公司 阿托伐他汀钙三水合物的制备方法
MY180626A (en) 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
CN104945300B (zh) * 2015-06-17 2017-05-10 北京嘉林药业股份有限公司 一种ⅰ型阿托伐他汀钙的纯化方法
CN105085362B (zh) * 2015-09-18 2018-01-05 浙江海森药业有限公司 高纯度结晶型阿托伐他汀钙的制备方法
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP3254219B2 (ja) * 1993-01-19 2002-02-04 ワーナー−ランバート・コンパニー 安定な経口用のｃｉ−９８１製剤およびその製法
GEP20002029B (en) 1995-07-17 2000-04-10 Warner Lambert Company Us (54) Crystalline [R-(R*,R*,]–2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methyl-Ethyl)-3-Phenyl–4-{Phenylamino) Carbonyl} - 1H - Pyrrole - 1 - Heptanoic Acid Hemi Calcium Salt (Atorvastatin)
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)

Also Published As

Publication number Publication date
YU35802A (sh) 2005-07-19
DE60018100D1 (en) 2005-03-17
EP1535613A3 (en) 2005-08-31
SK6742002A3 (en) 2003-05-02
SI1235799T1 (en) 2005-06-30
ATE478665T1 (de) 2010-09-15
IL149681A (en) 2007-06-17
AU783002B2 (en) 2005-09-15
SI1535613T1 (sl) 2010-12-31
ATE288893T1 (de) 2005-02-15
ZA200203755B (en) 2004-05-26
WO2001036384A1 (en) 2001-05-25
EP1235799A1 (en) 2002-09-04
ES2349364T3 (es) 2010-12-30
HUP0203257A2 (hu) 2003-01-28
EP1235799B1 (en) 2005-02-09
CA2392096A1 (en) 2001-05-25
JP2009102439A (ja) 2009-05-14
HRP20020429B1 (en) 2006-05-31
HUP0203257A3 (en) 2003-05-28
EP1235799A4 (en) 2003-05-28
EP1535613A2 (en) 2005-06-01
CA2392096C (en) 2008-07-15
PL355805A1 (en) 2004-05-17
PT1235799E (pt) 2005-05-31
IL149681A0 (en) 2002-11-10
SK286789B6 (sk) 2009-05-07
PT1535613E (pt) 2010-10-04
HRP20020429A2 (en) 2004-04-30
DE60044884D1 (de) 2010-10-07
DE60018100T2 (de) 2005-09-15
JP2003514798A (ja) 2003-04-22
CZ20021642A3 (cs) 2003-05-14
AU1617301A (en) 2001-05-30
ES2234699T3 (es) 2005-07-01
EP2206497A1 (en) 2010-07-14
EP1535613B1 (en) 2010-08-25
CN1423634A (zh) 2003-06-11
KR20020063190A (ko) 2002-08-01

Similar Documents

Publication Publication Date Title
HRP20020429B8 (hr) Polimorfni oblik atorvastatin kalcija
DE69908832D1 (de) Übertragung von Daten zur Übung musikalischer Aufführungen
NO20032758L (no) Krystallinske former av Atorvastatin
NO20023582D0 (no) Asymmetrisk syntese av pregabalin
AU2001231451A1 (en) Surgical sutures containing spider silk
DE69316894D1 (de) Wiederverwendbares endoskopisches, chirurgisches instrument
DE69918445D1 (de) Kalziumsalze enthaltende schweisshemmende zusammensetzungen
DE60117992D1 (de) Mechanochemische synthese von lithium enthaltendem mangandioxyd
DE60141776D1 (de) Trokaranordnung
EP1534695A4 (en) tyrosine kinase inhibitors
NO20023549L (no) Fremgangsmåte for rensing av 1,2-dikloretan
NO20040390L (no) Krystallinske former VI og VII av atorvastatinkalsium.
ID28779A (id) BENTUK-BENTUK KRISTAL DARI EtO2C-CH2-(R)CgL-Aze-Pab-OH
MXPA03008777A (es) El uso de escitalopram enantiomericamente puro.
DK1206436T3 (da) Retinoider til behandling af emfysem
DE60235280D1 (de) Demodulation von mehrträgerphasenmodulierten signalen
ATE240934T1 (de) Wasserhaltiges, kristallines calcium-salz der simvastatin dihydroxy offene säure
NO20035380D0 (no) Fremgangsmåte for dannelse av m degree nster
NO20042667L (no) Fremgangsmate for fremstilling av escitalopram
HRP20030853B1 (en) Crystalline form of omeprazole
NO20023837L (no) Modulering av bendannelse
DK1270575T3 (da) Hidtil ukendt krystallinsk form af et pyrrolidylthiocarbapenemderivat
IT1305003B1 (it) Punte per la perforazione del terreno con caratteristicheperfezionate per la rimozione dei detriti rocciosi prodotti e
DE69919049D1 (de) Herstellung von gefällten Kalziumkarbonatenthaltenden Produkten
DK0768304T3 (da) Hidtil ukendte sulfonamider

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
B8IS Corrected front page of an hr-b document
ODRP Renewal fee for the maintenance of a patent

Payment date: 20081115

Year of fee payment: 9

PBON Lapse due to non-payment of renewal fee

Effective date: 20091117